Cardiol Therapeutics Inc. (TSX:CRDL)
Canada · Delayed Price · Currency is CAD 1.810
-0.060 (-3.21%)
May 15, 2026, 4:00 PM EST
Cardiol Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
18
Market Cap
202.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 78.76K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ascend Wellness Holdings | 683.30M |
| Aurora Cannabis | 373.12M |
| TerrAscend | 365.43M |
| Organigram Global | 274.19M |
| Auxly Cannabis Group | 151.48M |
| Medexus Pharmaceuticals | 136.34M |
| Cannara Biotech | 113.01M |
| HLS Therapeutics | 77.81M |
Cardiol Therapeutics News
- 5 days ago - Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ - PRNewsWire
- 12 days ago - Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association - PRNewsWire
- 20 days ago - Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clinical Sites - GuruFocus
- 20 days ago - Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network - TheFly
- 21 days ago - Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program - PRNewsWire
- 4 weeks ago - Cardiol Therapeutics Transcript: Study result - Transcripts
- 5 weeks ago - Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart - Newsfile Corp
- 6 weeks ago - Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News - GuruFocus